



## 2nd Annual Needham Virtual Neuroscience Forum

Wednesday, March 15, 2023

Time (EDT)	<b>Fireside Chats</b> <i>Moderated by Ami Fadia, Managing Director, Biotech Equity Research at Needham</i>
8:00 - 8:35 AM	<b>Harmony Biosciences Holdings (HRMY)</b> w/ Jeffrey Dayno, Interim CEO & CMO
8:40 - 9:15 AM	<b>Denali (DNLI)</b> w/ Joe Lewcock, CSO
9:20 - 9:55 AM	<b>Anavex (AVXL)</b> w/ Christopher Missling, CEO
10:00 - 10:35 AM	<b>Acumen (ABOS)</b> w/ Daniel O'Connell, CEO w/ Eric Siemers, CMO
10:40 - 11:15 AM	<b>Althira (ATHA)</b> w/ Mark Litton, Ph.D., CEO w/ Kevin Church, Ph.D., VP-R&D
11:20 - 11:55 AM	<b>Axsome Therapeutics (AXSM)</b> w/ Herriot Tabuteau, MD., CEO
11:55 AM - 12:15 PM	<b>Break</b>
12:15 - 1:15 PM	<b>Physician Lunch Panel: Alzheimer's Disease</b> w/ Dr. Anton Porsteinsson
1:20 - 1:55 PM	<b>Impel (IMPL)</b> w/ John Leaman, CFO & CBO
2:00 - 2:35 PM	<b>Praxis (PRAX)</b> w/ Marcio Souza, CEO
2:40 - 3:15 PM	<b>Recursion (RXRX)</b> w/ Chris Gibson, CEO w/ Michael Secora, CFO
3:20 - 3:55 PM	<b>Stoke Therapeutics (STOK)</b> w/ Edward Kayne, MD, CEO w/ Barry Ticho, CMO
4:00 - 4:35 PM	<b>Ovid (OVID)</b> w/ Jeremy Levin, Chairman & CEO
Thank you for Attending	

## **Physician Lunch Panel on Alzheimer's Disease**

**Wednesday, March 15, 2023 (12:15 – 1:15 PM ET)**

*Moderated by: Ami Fadia, Managing Director, Biotech Equity Research at Needham & Company*

### **About this Panel:**

As part of our 2nd Annual Needham Virtual Neuroscience Forum, we are hosting a KOL discussion with **Dr. Anton Porsteinsson** to discuss his thoughts on recent developments and outlook of the Alzheimer's disease landscape. This Session will address:

- Commercial update of BiIB's LeqembiHow are emerging depression treatments differentiated from one another?
- Upcoming TRAILBLAZER-ALZ 2 data readout for LLY's donanemab
- Future clinical programs and other mechanism-of-action approaches to watch

### **KOL Expert Bio:**

**Dr. Anton Porsteinsson, M.D.:** Anton Porsteinsson, MD, is currently Director of the University of Rochester Alzheimer's Disease Care, Research and Education Program (AD-CARE) (1989 - Present). He is also the William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and Medicine at the University of Rochester School of Medicine and Dentistry (1989 - Present). Dr. Porsteinsson is internationally recognized in clinical research and considered one of the leading experts in Alzheimer's disease and dementia, and is a leading investigator for many prominent national Alzheimer's prevention and treatment trials. Dr. Porsteinsson received his MD degree from the University of Iceland School of Medicine and completed his internship and residency at the University of Rochester.